Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Catalyst Grant: Bioinformatics Approaches to Cancer Research

McGill University

$99,000.00

A molecular-level comparison of mouse models of breast cancer with the human disease via a de novo bioinformatics signature analysis tool

FY 2008-09

Summary
In recent years, microarrays, a technology that can measure the expression levels of all mRNAs in a sample, have been used to profile broad collections of tumors from women diagnosed with breast cancer. Taking advantage of this information, we propose to develop a bioinformatics tool (BreSAT) that is capable of identifying the important pathways, processes and cell types that are active in breast cancer. This is an important step towards the development of co-called multivariate biomarkers that are used by clinicians to gain deeper insight into the type and nature of indiviudal tumors. In turn, this helps clinicians optimize therapeutic regimes for patients. Over the past few years, the community has also generated analogous molecular portraits for tumors derived from mouse models of breast cancer. These mice have been genetically modified to reflect specific aspects of the disease, and play a pivotal role in research, since they allow us to explore the molecular mechanisms that initiate and drive tumor progression. In turn, our understanding of these mechanisms helps us devise new therapeutic approaches to treat the disease. Surprisingly, there has been little effort to compare human and mouse portraits in a systematic manner. We will apply our BreSAT tool to these mouse tumors and compare the results against the human profiles. This tool represents an important translational step that will allow basic researchers in molecular oncology to explore the value of their mouse model against all human clinical breast cancer samples. BreSAT uses a database of signatures that have been linked to components of tumor progression including cell growth, proliferation, immunological responses, invasiveness, and metastases. We describe a de novo method to find those molecular signatures that display a surprising degree of activation across the large panels of available mouse model and human samples.
Program
Catalyst Grant: Bioinformatics Approaches to Cancer Research
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
182346
Name
Hallett Michael T
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Catalyst Grant: Bioinformatics Approaches to Cancer Research
Projecttitle
A molecular-level comparison of mouse models of breast cancer with the human disease via a de novo bioinformatics signature analysis tool
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$99,000
Cihrequipment2
$0
Programname2
Catalyst Grant: Bioinformatics Approaches to Cancer Research
Keyworddelim
Analysis Tools; Bioinformatics; Breast Cancer; Mouse Models; Prognostic Markers; Signatures
Abstract
In recent years, microarrays, a technology that can measure the expression levels of all mRNAs in a sample, have been used to profile broad collections of tumors from women diagnosed with breast cancer. Taking advantage of this information, we propose to develop a bioinformatics tool (BreSAT) that is capable of identifying the important pathways, processes and cell types that are active in breast cancer. This is an important step towards the development of co-called multivariate biomarkers that are used by clinicians to gain deeper insight into the type and nature of indiviudal tumors. In turn, this helps clinicians optimize therapeutic regimes for patients. Over the past few years, the community has also generated analogous molecular portraits for tumors derived from mouse models of breast cancer. These mice have been genetically modified to reflect specific aspects of the disease, and play a pivotal role in research, since they allow us to explore the molecular mechanisms that initiate and drive tumor progression. In turn, our understanding of these mechanisms helps us devise new therapeutic approaches to treat the disease. Surprisingly, there has been little effort to compare human and mouse portraits in a systematic manner. We will apply our BreSAT tool to these mouse tumors and compare the results against the human profiles. This tool represents an important translational step that will allow basic researchers in molecular oncology to explore the value of their mouse model against all human clinical breast cancer samples. BreSAT uses a database of signatures that have been linked to components of tumor progression including cell growth, proliferation, immunological responses, invasiveness, and metastases. We describe a de novo method to find those molecular signatures that display a surprising degree of activation across the large panels of available mouse model and human samples.
Competitiondate
200903
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hallett, Michael T
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $99,000~ $0~